;PMID: 1364175 ;source_file_1768.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..37] = [t:0..37] ;1)sentence:[e:43..137] = [t:43..137] ;2)section:[e:141..161] = [t:141..161] ;3)section:[e:165..207] = [t:165..207] ;4)section:[e:211..270] = [t:211..270] ;5)sentence:[e:274..442] = [t:274..442] ;6)sentence:[e:443..549] = [t:443..549] ;7)sentence:[e:550..692] = [t:550..692] ;8)sentence:[e:693..772] = [t:693..772] ;9)sentence:[e:773..886] = [t:773..886] ;10)sentence:[e:887..1085] = [t:887..1085] ;11)section:[e:1089..1133] = [t:1089..1133] ;section 0 Span:0..37 ;Rev Med Chil. 1992 May;120(5):539-44. (SEC (FRAG (NNP:[0..3] Rev) (NNP:[4..7] Med) (NNP:[8..12] Chil) (.:[12..13] .) (CD:[14..18] 1992) (NNP:[19..22] May) (CD:[22..27] ;120-LRB-) (CD:[27..28] 5) (-RRB-:[28..29] -RRB-) (::[29..30] :) (CD:[30..33] 539) (HYPH:[33..34] -) (CD:[34..36] 44) (.:[36..37] .))) ;sentence 1 Span:43..137 ;[H2 antagonists as inhibitors of cytochrome P-450 in rat liver: in vitro and ;in vivo effects] ;[44..46]:substance:"H2" ;[47..58]:substance:"antagonists" ;[62..72]:substance:"inhibitors" ;[76..92]:cyp450:"cytochrome P-450" (SENT (NP-HLN (-LRB-:[43..44] -LSB-) (NP (NP (NN:[44..46] H2) (NNS:[47..58] antagonists)) (PP (IN:[59..61] as) (NP (NP (NNS:[62..72] inhibitors)) (PP (IN:[73..75] of) (NP (NN:[76..86] cytochrome) (NN:[87..92] P-450))) (PP-LOC (IN:[93..95] in) (NP (NN:[96..99] rat) (NN:[100..105] liver)))))) (::[105..106] :) (NP (NP (ADJP (FW:[107..109] in) (FW:[110..115] vitro)) (NML-1 (-NONE-:[115..115] *P*))) (CC:[116..119] and) (NP (ADJP (FW:[120..122] in) (FW:[124..128] vivo)) (NML-1 (NNS:[129..136] effects)))) (-RRB-:[136..137] -RSB-))) ;section 2 Span:141..161 ;[Article in Spanish] (SEC (FRAG (-LRB-:[141..142] -LSB-) (NN:[142..149] Article) (IN:[150..152] in) (NN:[153..160] Spanish) (-RRB-:[160..161] -RSB-))) ;section 3 Span:165..207 ;Carrasco M, Gaule C, Vega P, del Villar E. (SEC (FRAG (NNP:[165..173] Carrasco) (NNP:[174..176] M,) (NNP:[177..182] Gaule) (NNP:[183..184] C) (,:[184..185] ,) (NNP:[186..190] Vega) (NNP:[191..193] P,) (NNP:[194..197] del) (NNP:[198..204] Villar) (NNP:[205..207] E.))) ;section 4 Span:211..270 ;Servicio de Medicina Interna, Hospital Regional de Copiapo. (SEC (FRAG (NNP:[211..219] Servicio) (IN:[220..222] de) (NNP:[223..231] Medicina) (NNP:[232..239] Interna) (,:[239..240] ,) (NNP:[241..249] Hospital) (NNP:[250..258] Regional) (NNP:[259..261] de) (NNP:[262..269] Copiapo) (.:[269..270] .))) ;sentence 5 Span:274..442 ;Cytochrome P-50 is a well known participant in the metabolism of xenobiotics ;as well as an activator or inactivator of hepatotoxic substances and ;carcinogenic agents. ;[274..289]:cyp450:"Cytochrome P-50" ;[339..350]:substance:"xenobiotics" ;[366..375]:substance:"activator" ;[379..390]:substance:"inactivator" ;[406..416]:substance:"substances" ;[435..441]:substance:"agents" (SENT (S (NP-SBJ (NN:[274..284] Cytochrome) (NN:[285..289] P-50)) (VP (VBZ:[290..292] is) (NP-PRD (NP (NP (DT:[293..294] a) (ADJP (RB:[295..299] well) (VBN:[300..305] known)) (NN:[306..317] participant)) (PP (IN:[318..320] in) (NP (NP (DT:[321..324] the) (NN:[325..335] metabolism)) (PP (IN:[336..338] of) (NP (NNS:[339..350] xenobiotics)))))) (CONJP (RB:[351..353] as) (RB:[355..359] well) (IN:[360..362] as)) (NP (NP (DT:[363..365] an) (NN:[366..375] activator) (CC:[376..378] or) (NN:[379..390] inactivator)) (PP (IN:[391..393] of) (NP (NP (JJ:[394..405] hepatotoxic) (NNS:[406..416] substances)) (CC:[417..420] and) (NP (JJ:[421..433] carcinogenic) (NNS:[435..441] agents))))))) (.:[441..442] .))) ;sentence 6 Span:443..549 ;H2 antagonists, cimetidine, famotidine and ranitidine were used to inhibit ;cytochrome P-450 in rat liver. ;[443..445]:substance:"H2" ;[446..457]:substance:"antagonists" ;[459..469]:substance:"cimetidine" ;[471..481]:substance:"famotidine" ;[486..496]:substance:"ranitidine" ;[519..535]:cyp450:"cytochrome P-450" (SENT (S (NP-SBJ-1 (NP (NN:[443..445] H2) (NNS:[446..457] antagonists)) (,:[457..458] ,) (NP (NN:[459..469] cimetidine) (,:[469..470] ,) (NN:[471..481] famotidine) (CC:[482..485] and) (NN:[486..496] ranitidine))) (VP (VBD:[497..501] were) (VP (VBN:[502..506] used) (NP-1 (-NONE-:[506..506] *)) (S-PRP (NP-SBJ (-NONE-:[506..506] *)) (VP (TO:[507..509] to) (VP (VB:[511..518] inhibit) (NP (NN:[519..529] cytochrome) (NN:[530..535] P-450)) (PP-LOC (IN:[536..538] in) (NP (NN:[539..542] rat) (NN:[543..548] liver)))))))) (.:[548..549] .))) ;sentence 7 Span:550..692 ;After 200 mg cimetidine, 85% inhibition of cytochrome P-450 in vitro and 50% ;in vivo were demonstrated through demethylation of aminopyrine. ;[556..559]:quantitative-value:"200" ;[560..562]:quantitative-units:"mg" ;[563..573]:substance:"cimetidine" ;[575..578]:quantitative-value:"85%" ;[594..610]:cyp450:"cytochrome P-450" ;[624..627]:quantitative-value:"50%" ;[680..691]:substance:"aminopyrine" (SENT (S (PP-TMP (IN:[550..555] After) (NP (NML (CD:[556..559] 200) (NN:[560..562] mg)) (NN:[563..573] cimetidine))) (,:[573..574] ,) (NP-SBJ-2 (NP (NP (NP (NML (CD:[575..577] 85) (NN:[577..578] %)) (NN:[579..589] inhibition)) (PP (IN:[591..593] of) (NP (NN:[594..604] cytochrome) (NN:[605..610] P-450)))) (ADJP (FW:[611..613] in) (FW:[614..619] vitro))) (CC:[620..623] and) (NP (NP (CD:[624..626] 50) (NN:[626..627] %)) (ADJP (FW:[628..630] in) (FW:[631..635] vivo)))) (VP (VBD:[636..640] were) (VP (VBN:[641..653] demonstrated) (NP-2 (-NONE-:[653..653] *)) (PP-MNR (IN:[654..661] through) (NP (NP (NN:[663..676] demethylation)) (PP (IN:[677..679] of) (NP (NN:[680..691] aminopyrine))))))) (.:[691..692] .))) ;sentence 8 Span:693..772 ;Inhibition was further confirmed by differential absorption spectra (Type ;II). (SENT (S (NP-SBJ-1 (NN:[693..703] Inhibition)) (VP (VBD:[704..707] was) (ADVP (RBR:[708..715] further)) (VP (VBN:[716..725] confirmed) (NP-1 (-NONE-:[725..725] *)) (PP (IN:[726..728] by) (NP-LGS (NP (JJ:[729..741] differential) (NN:[743..753] absorption) (NNS:[754..761] spectra)) (PRN (-LRB-:[762..763] -LRB-) (NP (NN:[763..767] Type) (CD:[768..770] II)) (-RRB-:[770..771] -RRB-)))))) (.:[771..772] .))) ;sentence 9 Span:773..886 ;The percentage inhibition obtained with famotidine or ranitidine were lower ;than those obtained with cimetidine. ;[813..823]:substance:"famotidine" ;[828..838]:substance:"ranitidine" ;[875..885]:substance:"cimetidine" (SENT (S (NP-SBJ (NP (DT:[773..776] The) (NN:[777..787] percentage) (NN:[788..798] inhibition)) (VP (VBN:[799..807] obtained) (NP (-NONE-:[807..807] *)) (PP-MNR (IN:[808..812] with) (NP (NN:[813..823] famotidine) (CC:[825..827] or) (NN:[828..838] ranitidine))))) (VP (VBD:[839..843] were) (ADJP-PRD (ADJP (JJR:[844..849] lower)) (PP (IN:[850..854] than) (NP (NP (DT:[855..860] those)) (VP (VBN:[861..869] obtained) (NP (-NONE-:[869..869] *)) (PP-MNR (IN:[870..874] with) (NP (NN:[875..885] cimetidine)))))))) (.:[885..886] .))) ;sentence 10 Span:887..1085 ;Inhibition of the microsomal oxidative system by cimetidine could lead to ;decreased production of superoxide radicals and protection against damage ;induced by toxic agents activated in the liver. ;[937..947]:substance:"cimetidine" ;[987..1006]:substance:"superoxide radicals" ;[1054..1060]:substance:"agents" (SENT (S (NP-SBJ (NP (NN:[887..897] Inhibition)) (PP (IN:[898..900] of) (NP (DT:[901..904] the) (JJ:[906..916] microsomal) (JJ:[917..926] oxidative) (NN:[927..933] system))) (PP (IN:[934..936] by) (NP (NN:[937..947] cimetidine)))) (VP (MD:[948..953] could) (VP (VB:[954..958] lead) (PP-CLR (TO:[959..961] to) (NP (NP (NP (VBN:[962..971] decreased) (NN:[972..982] production)) (PP (IN:[983..985] of) (NP (NN:[987..997] superoxide) (NNS:[998..1006] radicals)))) (CC:[1007..1010] and) (NP (NP (NN:[1011..1021] protection)) (PP (IN:[1022..1029] against) (NP (NP (NN:[1030..1036] damage)) (VP (VBN:[1037..1044] induced) (NP (-NONE-:[1044..1044] *)) (PP (IN:[1045..1047] by) (NP-LGS (NP (JJ:[1048..1053] toxic) (NNS:[1054..1060] agents)) (VP (VBN:[1062..1071] activated) (NP (-NONE-:[1071..1071] *)) (PP-LOC (IN:[1072..1074] in) (NP (DT:[1075..1078] the) (NN:[1079..1084] liver)))))))))))))) (.:[1084..1085] .))) ;section 11 Span:1089..1133 ;PMID: 1364175 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1089..1093] PMID) (::[1093..1094] :) (CD:[1095..1102] 1364175) (NN:[1103..1104] -LSB-) (NNP:[1104..1110] PubMed) (::[1111..1112] -) (NN:[1113..1120] indexed) (IN:[1121..1124] for) (NNP:[1125..1133] MEDLINE-RSB-)))